Resources

Cancer growth blockers (tyrosine kinase inhibitors and proteasome inhibitors)

Registered clinical trials on gefitnib
http://clinicaltrials.gov/ct2/results?term=gefitnib

Prescribing Information for gefitnib
http://www1.astrazeneca-us.com/pi/iressa.pdf

FDA Postmarketing Information on gefitnib
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085197.htm

Astra Zeneca Financial Report
http://www.astrazeneca-annualreports.com/2008/directors_report/therapy_area_review/oncology/financial_perf.html

References

(1) Morita S, Okamoto I, Kobayashi K et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations

Research

Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.